$18.600
+0.253 (+1.36%)終値時点
- 高値
- 20.000
- 始値
- 19.020
- 出来高加重平均価格
- 19.00
- 出来高
- 11.96K
- 時価総額
- —
- 安値
- 18.400
- 売買代金
- 227.20K
- EV/EBITDA（TTM）
- 0.00
Mentari Therapeutics, Inc., a biotechnology company, develops and provides therapies for migraine prevention. The company's products include MT-001, an anti-PACAP monoclonal antibody designed for convenient subcutaneous dosing; MT-002, an anti-CGRP; and anti-PACAP bispecific antibody designed to inhibit these complementary pathways. The company was incorporated in 2025 and is based in Sacramento, California.
バリュエーション指標
MTRI のよくある質問 — Alphio AI が回答
Mentari Therapeutics, Inc., a biotechnology company, develops and provides therapies for migraine prevention. The company's products include MT-001, an anti-PACAP monoclonal antibody designed for convenient subcutaneous dosing; MT-002, an anti-CGRP; and anti-PACAP bispecific antibody designed to inhibit these complementary pathways. The company was incorporated in 2025 and is based in Sacramento, California.
コミュニティ
もっと見る ↗投稿はまだありません
登録またはログインして議論に参加関連記事
- Dollar-Cost Averaging vs Lump Sum: How to Invest Cash in a Volatile, High-Yield 2026 MarketDollar cost averaging vs lump sum in a volatile 2026 market: what Vanguard's research shows, how 4%+ T-bill yields change the math, and how to build a plan.
- Stock Market Outlook 2027: What Wall Street's S&P 500 Forecasts Really Tell InvestorsStock market outlook 2027: what Goldman, UBS, BofA and bears forecast for the S&P 500, the earnings math behind targets, and how to plan for any scenario.
- REITs and Rising Interest Rates in 2026: Why Real Estate Stocks Are Holding Up and Where the Risks AHow rising interest rates affect REITs in 2026: why REITs are up despite Fed hikes, which sectors hold up, how to value REITs and build a rate-aware allocation.
本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。